Literature DB >> 15765344

After the black box warning: dramatic changes in ED use of droperidol.

Jeanne L Jacoby1, Jessica Fulton, Mark Cesta, Michael Heller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15765344     DOI： 10.1016/j.ajem.2004.09.019

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN： 0735-6757            Impact factor:   2.469


× No keyword cloud information.
  6 in total

1.  Effectiveness of safety warnings in atypical antipsychotic drugs: an interrupted time-series analysis in Spain.

Authors:  Gabriel Sanfélix-Gimeno; Pedro Cervera-Casino; Salvador Peiró; Beatriz González López-Valcarcel; Amparo Blázquez; Teresa Barbera
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

2.  Different black box warning labeling for same-class drugs.

Authors:  Orestis A Panagiotou; Despina G Contopoulos-Ioannidis; Panagiotis N Papanikolaou; Evangelia E Ntzani; John P A Ioannidis
Journal:  J Gen Intern Med       Date:  2011-02-01       Impact factor: 5.128

3.  Ambulatory Fluoroquinolone Use in the United States, 2015-2019.

Authors:  Siddhi Pramod Umarje; Caleb G Alexander; Andrew J Cohen
Journal:  Open Forum Infect Dis       Date:  2021-10-23       Impact factor: 3.835

4.  Impact of FDA black box advisory on antipsychotic medication use.

Authors:  E Ray Dorsey; Atonu Rabbani; Sarah A Gallagher; Rena M Conti; G Caleb Alexander
Journal:  Arch Intern Med       Date:  2010-01-11

5.  Acute gastroenteritis: from guidelines to real life.

Authors:  Chung M Chow; Alexander Kc Leung; Kam L Hon
Journal:  Clin Exp Gastroenterol       Date:  2010-07-15

6.  Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling.

Authors:  Matthew J Higgins; Xin Yan; Chirantan Chatterjee
Journal:  Res Policy       Date:  2020-09-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.